General description
LATS1 is a putative serine/threonine kinase that localizes to the mitotic apparatus and complexes with cell cycle controller CDC2 kinase in early mitosis which is phosphorylated in a cell-cycle dependent manner. The N-terminal region of the protein binds CDC2 to form a complex showing reduced H1 histone kinase activity which indicating a role as a negative regulator of CDC2/cyclin A and the C-terminal kinase domain binds to its own N-terminal region, suggesting potential negative regulation through interference with complex formation via intramolecular binding. LATS1 act as a tumor suppressor and play an important role in the development of soft-tissue sarcomas, ovarian stromal cell tumors and a high sensitivity to carcinogenic treatments.
Physical form
Supplied in 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10 mM glutathione, 0.1 mM EDTA, 0.25 mM DTT, 0.1 mM PMSF, 25% glycerol.
Preparation Note
After opening, aliquot into smaller quantities and store at -70 °C. Avoid repeating handling and multiple freeze/thaw cycles.
Legal Information
PRECISIO is a registered trademark of Merck KGaA, Darmstadt, Germany
| recombinant | expressed in baculovirus infected Sf9 cells |
| product line | PRECISIO® |
| assay | ≥70% (SDS-PAGE) |
| form | buffered aqueous glycerol solution |
| specific activity | 1.1-1.7 nmol/min·mg |
| mol wt | ~95 kDa |
| NCBI accession no. | NM_004690 |
| shipped in | dry ice |
| storage temp. | −70°C |
| Gene Information | human ... LATS1(9113) |
